Table 4.
Predictive factors for improvement of frail phenotype at the end of the study. OR: odds ratio; CI: confidence interval; CD: Crohn’s disease; UC: ulcerative colitis; BMI: body mass index; EIMs: extraintestinal manifestations; ISS: immunosuppressors.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| Risk Factors | OR (95% CI) | p-Value | OR (95% CI) | p-Value |
| Age (years) | 0.97 (0.9–1.0) | 0.26 | - | - |
| Female gender | 0.6 (0.1–2.2) | 0.41 | - | - |
| CD | 0.95 (0.2 3–6) | 0.94 | - | - |
| UC | 1.1 (0.3–4.1) | 0.95 | - | - |
| Duration of disease (months) | 1.0 (0.9–1.0) | 0.96 | - | - |
| BMI (kg/m2) | 1.0 (0.9–1.2) | 0.93 | - | - |
| History of EIMs | 0.2 (0.04–0.7) | 0.02 | 0.1 (0.02–0.8) | 0.04 |
| History of steroid dependence/resistance | 1.5 (0.4–6.5) | 0.52 | - | - |
| Clinically active disease | 0.2 (0.03–0.6) | 0.01 | 0.1 (0.01–0.6) | 0.02 |
| Current therapy with steroids | 1.2 (0.2–24.1) | 0.88 | - | - |
| Current therapy with biologic agents | 7.8 (1.9–40.2) | 0.007 | 21.7 (3.4–263) | 0.004 |
| Current therapy with ISS | 0.7 (0.08–14.6) | 0.75 | - | - |
| Current therapy with mesalamine | 1.1 (0.3–4.3) | 0.88 | - | - |
| Charlson comorbidity index | 0.7 (0.4–1.1) | 0.10 | - | - |
| Psychiatric diseases | 1.1 (0.2–7.8) | 0.94 | - | - |
| Heart failure | 0.4 (0.04–10.1) | 0.52 | - | - |
| Pneumological diseases | 1.2 (0.2–24.1) | 0.88 | - | - |
| Neurodegenerative diseases | 0.4 (0.04–10.1) | 0.52 | - | - |
| Post-COVID fatigue | 0.2 (0.02–1.8) | 0.13 | - | - |